Biovie (BIVI) Other Non Operating Income (2017 - 2025)
Biovie (BIVI) posted Other Non Operating Income of $7290.0 for Q1 2025, up 220.78% sequentially from -$6036.0 in Q4 2024, and down 93.31% YoY from $109003.0 in Q1 2024.
Biovie (BIVI) Other Non Operating Income (2017 - 2025) Analysis & Trends
Biovie has reported Other Non Operating Income for 9 years, with the latest figure at $7290.0 in Q1 2025.
- Quarterly Other Non Operating Income fell 93.31% year-over-year to $7290.0 in Q1 2025, while the trailing twelve-month figure through Jun 2025 was $3771.0 (down 99.79% YoY) and the FY2025 annual result came in at $3771.0, down 99.79% from the prior year.
- Other Non Operating Income advanced to $7290.0 in Q1 2025 per BIVI's latest filing, from -$6036.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $2.7 million in Q2 2023 and troughed at -$3.2 million in Q4 2022.
- A 5-year average of $262141.4 and a median of $12111.0 in 2024 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2022 and 2023: Other Non Operating Income sank 307.17% in 2022, then jumped 224.93% in 2023.
- Over 5 years, Other Non Operating Income stood at $1.6 million in 2021, then tumbled by 307.17% to -$3.2 million in 2022, then jumped by 130.49% to $982534.0 in 2023, then tumbled by 100.61% to -$6036.0 in 2024, then jumped by 220.78% to $7290.0 in 2025.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $7290.0, -$6036.0, and $2517.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 7,290.00 |
| Dec 31, 2024 | -6,036.00 |
| Sep 30, 2024 | 2,517.00 |
| Jun 30, 2024 | 16,932.00 |
| Mar 31, 2024 | 109,003.00 |
| Dec 31, 2023 | 982,534.00 |
| Sep 30, 2023 | 707,802.00 |
| Jun 30, 2023 | 2.72 Mn |
| Mar 31, 2023 | -366,093.00 |
| Dec 31, 2022 | -3.22 Mn |
| Sep 30, 2022 | -566,542.00 |
| Jun 30, 2022 | 2.12 Mn |
| Mar 31, 2022 | -386,450.00 |
| Dec 31, 2021 | 1.56 Mn |
| Sep 30, 2020 | 8.28 Mn |
| Jun 30, 2020 | -17.34 Mn |
| Mar 31, 2020 | 366,550.00 |
| Dec 31, 2019 | 7.40 Mn |
| Sep 30, 2019 | 362,586.00 |
| Sep 30, 2018 | 51,400.00 |